Foley & Lardner LLP
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAAE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.
Memorial Sloan Kettering Cancer Center
A A A A A A A A C A A A A C A A C A C C C
A61P A61K A61K A61K A61K A61P A61P A61K C12N A61P A61P A61K A61K C07K A61K A61K C12N A61P C12N C07K C12N
inventional inventional additional additional additional inventional inventional additional additional inventional inventional additional inventional inventional additional inventional additional inventional additional inventional additional
Jedd Liang Weiyi Peihong Stewart Taha
Wolchok Deng Wang Dai Shuman Merghoub